Avet Pharmacceuticals Inc., Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Avet Pharmacceuticals Inc., Pharmaceutical Import Records from India — 5 Products, $7.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Avet Pharmacceuticals Inc., — Pharmaceutical Importer Profile (2026) | 5 Products, $7.0M Trade | TransData Nexus

Avet Pharmacceuticals Inc.,

Pharmaceutical Importer · United States · Immunosuppressants Focus · $7.0M Total Trade · DGFT Verified

Avet Pharmacceuticals Inc., is a pharmaceutical importer based in United States with a total trade value of $7.0M across 5 products in 4 therapeutic categories. Based on 149 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Avet Pharmacceuticals Inc., sources from 3 verified Indian suppliers, with Strides Pharma Science Limited accounting for 96.7% of imports.

Avet Pharmacceuticals Inc., — Import Portfolio & Supplier Network

Avet Pharmacceuticals Inc., import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Avet Pharmacceuticals Inc.,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Strides Pharma Science Limited	$6.4M	181	96.7%
Strides Alathur Private Limited	$130.6K	3	2.0%
Cohance Lifesciences Limited	$84.6K

What Formulations Does Avet Pharmacceuticals Inc., Import?

Formulation	Value	Ships
Calcitriol capsules 0.25mcg soft	$270.3K	6
Cyclosporine capsules USP 100 MG (modified) [sgc] - us - anda no: 216046 ndc	$250.0K	5
Mycophenolate mofetil tablets USP 500MG	$200.0K	4
Mycophenolate mofetil tablets USP [500MG] [fc] [us] - anda no : 90456 ndc no : 23155-836-01.	$200.0K	4
Vancomycin hydrochloride capsules usp125mgushard gelatin Each hard gelatincapsule contains vancomycin	$167.7K	5
Calcitriol capsules 0.5mcg soft	$150.0K	3
Cyclosporine capsules USP 25 MG	$150.0K	3
Mycophenolate mofetil tablets USP 500MG fc us Each film coated tablet contains mycophenolate mofetil USP 500MG.	$150.0K	3
Vancomycin hydrochloride capsules USP 125MG us hard gelatin-Each hard gelatin capsule contains	$148.4K	3
Nystatin oral tablets usp5,00,000 units (27216 x 1 x 100s)	$130.6K	3
Ergocalciferol capsules USP 1.25MG	$100.0K	2
Mycophenolate mofetil tablets usp500mg	$100.0K	2
Mycophenolate mofetil tablets USP 500MG fc us Each film coated tablet contains mycophenolate mofetil USP 500MG	$100.0K	2
Cyclosporine capsules USP 25 MG (modified) sgc - us Each soft gelatin capsulescontains cyclosporine USP 25 MG 26,550.	$100.0K	2
Cyclosporine capsules USP 25 MG (modified) sgc - us Each soft gelatin capsulescontains cyclosporine USP 25 MG 27,000.	$100.0K	2

Avet Pharmacceuticals Inc., imports 129 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Cyclosporine	Immunosuppressants	$2.8M	60	13.2%	2
2	Mycophenolate	Immunosuppressants	$2.0M	40	0.4%	9
3	Nystatin	Antifungals	$1.0M	20	1.9%	6
4	Vancomycin	Antibiotics	$896.3K	23	1.0%	17
5	Colchicine	Lipid & Metabolism	$300.0K	6	1.4%	10

Avet Pharmacceuticals Inc., imports 5 pharmaceutical products across 4 categories into United States totaling $7.0M.

Avet Pharmacceuticals Inc., — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Avet Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company headquartered in East Brunswick, New Jersey. Established in 2006, the company specializes in the acquisition, development, marketing, sale, and distribution of generic pharmaceutical products for the U.S. prescription drug market. Avet's mission is to provide affordable, accessible, and high-quality medicines that enhance health outcomes and improve patient lives.

The company's product portfolio spans multiple therapeutic categories, including cardiovascular, oncology, metabolic diseases, anti-infectives, and pain management. Avet offers a range of oral solids and liquids, as well as injectables, catering to diverse patient needs. With a global supply chain network, Avet collaborates with FDA-approved manufacturing partners in North America, Europe, and Asia to ensure the highest standards of quality, safety, value, and service in generics.

2Distribution Network

Avet Pharmaceuticals operates from its headquarters in East Brunswick, New Jersey, and maintains multiple facilities within the region. The company has distribution centers at 16 Elkins Road, 21 Cotters Lane, and 8 Elkins Road, all located in East Brunswick, New Jersey. While specific details about warehouse locations and logistics capabilities beyond these facilities are not publicly disclosed, Avet's strategic outsourcing to FDA-approved manufacturing partners in North America, Europe, and Asia suggests a well-established and efficient distribution network.

3Industry Role

Avet Pharmaceuticals Inc. functions primarily as a pharmaceutical importer and distributor within the United States. The company focuses on acquiring, developing, and marketing generic pharmaceutical products, sourcing them from various international suppliers, including those in India. By importing finished pharmaceutical formulations, Avet plays a crucial role in enhancing the availability of affordable generic medications in the U.S. market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Avet Pharmacceuticals Inc.,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Avet Pharmaceuticals demonstrates a high degree of sourcing concentration, with a significant portion of its imports originating from a single supplier, Strides Pharma Science Limited. Between 2022 and 2026, Avet imported approximately $6.4 million worth of pharmaceutical products from Strides, accounting for 96.7% of its total imports from India. This concentration indicates a strong reliance on Strides for its product supply. The stability of this relationship is evidenced by the consistent number of shipments over the years, suggesting a reliable and ongoing partnership. However, such dependency may pose risks related to supply chain disruptions or changes in supplier dynamics.

2Supply Chain Resilience

Avet Pharmaceuticals' supply chain resilience appears robust, primarily due to its strategic partnership with Strides Pharma Science Limited, a major supplier. The consistent volume of imports and the diversity of formulations—129 unique formulations—indicate a well-managed supply chain capable of meeting diverse market demands. While the heavy reliance on a single supplier could be a potential risk, the company's diversified product portfolio and established logistics infrastructure suggest a capacity to adapt to supply chain challenges.

Strategic Implications

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth the legal framework for drug imports. Pharmaceutical imports must comply with FDA standards for quality, safety, and effectiveness. Drugs imported into the U.S. must be approved by the FDA, either through a New Drug Application (NDA) or an Abbreviated New Drug Application (ANDA), and must be manufactured in facilities registered with the FDA.

2Import Licensing & GMP

Importers of pharmaceutical products into the United States must ensure that their foreign suppliers are registered with the FDA and that their products are listed with the agency. Additionally, the FDA requires that imported drugs meet Good Manufacturing Practice (GMP) standards. Recognized GMP certifications include those from the European Union (EU GMP), the World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must verify that their suppliers hold valid GMP certifications from these recognized bodies to ensure compliance with FDA regulations.

Quality & Labeling

Avet Pharmacceuticals Inc., — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Avet Pharmaceuticals' focus on importing immunosuppressants, antifungals, and antibiotics aligns with the company's strategic objective to address critical therapeutic areas with high unmet needs. The substantial import value of cyclosporine, mycophenolate, and nystatin indicates a targeted approach to providing essential medications in these categories. Market demand for these products is driven by the prevalence of conditions such as organ transplant rejection, autoimmune disorders, and fungal infections, necessitating a reliable supply of effective treatments.

2Sourcing Profile

Avet Pharmaceuticals' sourcing strategy emphasizes the importation of finished pharmaceutical formulations, particularly generic drugs, from India. This approach leverages India's established pharmaceutical manufacturing capabilities and cost advantages. The company's preference for sourcing from India is evident in the significant import value and volume of products from Indian suppliers, indicating a strategic alignment with India's strengths in pharmaceutical production.

3Market Positioning

Based on its product mix, Avet Pharmaceuticals serves a broad segment of the U.S. pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's focus on essential therapeutic categories positions it to meet the diverse needs of healthcare providers and patients, ensuring the availability of affordable and effective generic medications across various healthcare settings.

Seller's Guide — How to Become a Supplier to Avet Pharmacceuticals Inc.,

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Avet Pharmaceuticals, especially if they can offer high-quality generic formulations that meet FDA standards. Gaps in Avet's current sourcing may exist in areas where additional suppliers can provide competitive pricing or unique product offerings. Indian exporters can explore these opportunities by ensuring compliance with FDA regulations and demonstrating the ability to meet Avet's quality and supply chain requirements.

2Requirements & Qualifications

Indian exporters seeking to supply Avet Pharmaceuticals and the U.S. market must ensure that their manufacturing facilities are registered with the FDA and that their products are listed with the agency. They must hold valid GMP certifications from recognized bodies such as EU GMP, WHO GMP, or PIC/S. Additionally, products must comply with FDA labeling requirements, including accurate and informative labeling in English. Batch testing, stability studies, and serialization may also be required to meet FDA standards.

3How to Approach

Frequently Asked Questions — Avet Pharmacceuticals Inc.,

What products does Avet Pharmacceuticals Inc., import from India?

Avet Pharmacceuticals Inc., imports 5 pharmaceutical products across 4 categories. Top imports: Cyclosporine ($2.8M), Mycophenolate ($2.0M), Nystatin ($1.0M), Vancomycin ($896.3K), Colchicine ($300.0K).

Who supplies pharmaceuticals to Avet Pharmacceuticals Inc., from India?

Avet Pharmacceuticals Inc., sources from 3 verified Indian suppliers. The primary supplier is Strides Pharma Science Limited (96.7% of imports, $6.4M).

What is Avet Pharmacceuticals Inc.,'s total pharmaceutical import value?

Avet Pharmacceuticals Inc.,'s total pharmaceutical import value from India is $7.0M, based on 149 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Avet Pharmacceuticals Inc., focus on?

Avet Pharmacceuticals Inc., imports across 4 categories. The largest: Immunosuppressants (68.8%), Antifungals (14.2%), Antibiotics (12.7%).

Get Full Avet Pharmacceuticals Inc., Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.